The antitumor activity of cis-diamminedichloroplatinum II (cisplatin) is believed to be related to its covalent interaction with DNA where a major DNA binding product is an intrastrand N7-bidentate adduct on adjacent deoxyguanosines. A novel immunoassay was used to quantitate this adduct in buffy coat DNA from testicular and ovarian cancer patients undergoing cisplatin therapy. 44 out of 120 samples taken from 45 
Introduction cis-Diamminedichloroplatinum II (cisplatin),' a potent anticancer agent, is the principal agent in the treatment oftesticular (1) and ovarian cancers (2, 3) , and is useful for several other malignancies (4) (5) (6) (7) . Novel methods of drug administration have allowed dosages to increase with acceptable toxicity (8-1 1), thus broadening the potential clinical spectrum. In vitro studies have modification, which includes formation of interstrand cross-links and intrastrand adducts (12, 13) . A bidentate, N7-deoxy (GpG) intrastrand platinum adduct is found in DNA from cultured cells and from animal tissues following cisplatin exposure (14) (15) (16) . In cisplatin-exposed cultured L12 10 cells, this adduct comprises up to 60% of the total cisplatin-DNA modification determined by high-pressure liquid chromatography (15) . We have prepared and characterized a rabbit antiserum with primary specificity for the N7-deoxy(GpG) intrastrand adduct (16). Using enzyme-linked immunosorbent assay (ELISA), with modifications outlined below, it has been possible to quantitate this adduct in DNA isolated from several different sources at a sensitivity of one adduct in 108 nucleotides or 25 attomol/flg DNA (14, 16, 17) . This level of detectability has provided the unique opportunity to attempt to measure DNA modification in tissues from patients receiving cisplatin chemotherapy, and to look for a correlation between adduct formation and disease response. While tumor samples would be the most appropriate to measure, such tissues are not readily obtainable and would not allow for repetitive samplings. Therefore we chose to monitor cisplatin-DNA adduct formation in nucleated cells obtained from the buffy coat of the readily accessible peripheral blood of chemotherapy patients.
Methods
Cisplatin administration to patient groups. Individuals studied were being treated for either ovarian or testicular cancer by the Medicine Branch of the National Cancer Institute. These patients were given cisplatin therapy as part of approved experimental protocols and comprised the following groups: (a) cisplatin, velban, bleomycin (PVB)/cisplatin, epidophyllotoxin, bleomycin, velban (PVeBV), testicular cancer patients receiving their first course of chemotherapy on 21-d (PVB) or 28- Cisplatin chemotherapy was given in courses comprised of three to five cycles. In each cycle the drug was administered as a 30-min daily intravenous infusion on each of five consecutive days and no cisplatin was given for the remainder of the cycle. The drug was administered in standard fashion (1) for dose regimens of 20 mg/M2 per day X 5 and 30 mg/Ml per day' X 5, and in "high dose" fashion (9) Cisplatin was given as a 1-h infusion daily on days I through 5 of the cycle. Samples were collected in the morning of the day following (12-18 h after) the infusion. Day I samples were collected before any cisplatin was administered. DNA samples were prepared and ELISAs performed as described in Methods.
random during the treatment cycle. Fig. 1 shows adduct accumulation in DNA samples from previously untreated patients studied on the first cycle of their first course of cisplatin chemotherapy. There is a greater proportion of positive samples toward the end of a cycle, suggesting that adduct levels increase with successive doses of cisplatin. Since 35-50 ml of blood was drawn for each adduct determination, it was not feasible to study a single patient on each of the five days following cisplatin infusions. However, these data demonstrated that maximum adduct levels could be expected the day after the last infusion, and subsequent samples were obtained at this time. Even at this point, only 60% of the patients were positive by this assay. Measurable cisplatin-DNA adducts in positive samples from patients in each of the four treatment groups is plotted in Fig. 2 (Fig. 2, A and B) , while the correlation is less clear in patients on 56-d cycles or those who have failed previous chemotherapy (Fig. 2, C and D) . Linear regression analyses of the data for testicular (Fig. 2 A) and ovarian (Fig. 2 B) cancer patients receiving their first course of chemotherapy on 21-or 28-d cycles shows that blood cell DNA adducts appeared to increase in a dose-dependent fashion. The slopes and correlation coefficients for the adduct accumulation data in the two groups are virtually identical. For patients receiving their first course ofchemotherapy on 56-d cycles (Fig. 2 C) , the data points show considerable scatter, resulting in a correlation coefficient of only 0.48. This increase in measurable adduct levels appears to be less consistent when patients have a longer cycle time interval, suggesting that substantial adduct removal does occur within the 56-d time period. For samples from patients receiving cisplatin as a single agent, having failed one or more courses of chemotherapy previously (Fig. 2 D) , adducts increased slowly with cisplatin dose. This is illustrated by the slope which is less than half of, and the correlation coefficient which is substantially lower than, values for the groups in Fig. 2 A and Combined values for positive samples from all patients receiving chemotherapy for the first time on 21-or 28-d cycles (Fig. 2, A and B) are presented in Fig. 3 as a function of (A) cumulative cisplatin dose or (B) the cycle of treatment. Linear regression analysis of the data in Fig. 3 B shows good linear fit, illustrating that adducts accumulate as a function of cycle. These data imply that cisplatin-DNA adduct removal is slow, and that some adducts persist for at least 28 d.
Correlation between response to cisplatin treatment and adductformation. Disease response data are available on 33 of the cisplatin patients from whom blood was drawn for ELISA. Of these, 12 were given cisplatin as a single agent, and 21 were exposed to combination chemotherapy that included cisplatin. Table II shows disease response data for these patients, grouped by single agent vs. combination chemotherapy, and separated by groups into those who never showed measurable adduct levels and those who had at least one positive adduct determination blood has several different types of nucleated cells, we sought to to attomoles of adduct measured in a given portion of DNA. In determine if a relative change in the number of short-lived or aliquots of L12 10 cells mixed with human buffy coats, the atlong-lived cells might explain variation in adduct levels in the tomole adduct/cpm ratio was 29.9±7 (mean±SD). In aliquots samples studied. To address this question, we reviewed the medof the Ll2 10 controls the ratio was 34.6±7. Thus the presence ical records of 9 patients whose blood DNA was never positive of the buffy coat cells did not affect the yield of cisplatin-DNA in the assay and 10 patients from matched treatment protocols adducts. In addition, the yield of DNA was not altered by the (Fig. 2 C) . This suggests that substantial removal of this adduct from circulating cells occurs within the 56-d cycle interval. As regards the dose regimen, the data presented here lends itselfto several projections. Many cancer centers currently treat certain malignancies with a cisplatin regimen of a single infusion per cycle with a dose >100 mg/M2, including lung cancer (4), head and neck malignancies (5) , and others (6) . How adduct persistence may be affected by single cisplatin doses of this magnitude is unclear. In one study on ovarian cancer, similar disease response rates were seen between two cisplatin regimens, one containing a single cisplatin infusion per cycle and the other having daily infusions for 5 d (30) . The former regimen resulted in half the total cisplatin dose of the latter. If further study should bear out the value of adduct measurements, one could ascertain the adduct profiles generated by different treatment regimens and perhaps treat with the less toxic regimen while assuring comparable antitumor activity.
Of the many possible sequelae cisplatin may produce, one of the most ominous is the generation of second malignancies, reports of which have begun to appear in the literature (26, 27) . It is possible that the slow rate of intrastrand adduct removal may contribute to the chemotherapeutic potency of cisplatin. However, this adduct persistency may also be related to the eventual development of treatment-related neoplasia since similar phenomena are known to occur in animal models. For example, in neonatal rats exposed to ethylnitrosourea, a neurooncogenic effect in brain tissue has been shown to correlate directly with the slow rate of repair of the ethylnitrosourea-DNA adduct (28) . If reports of cisplatin-related neoplasia become more frequent, this adduct persistency may well pose a difficult therapeutic dilemma. Data generated in studies such as ours may be useful in determining dose-response relationships and adduct accumulation levels associated with risks for second malignancies.
Studies using the ELISA to quantitate adducts in animal models may become useful adjuncts for designing drug treatment protocols and for elucidating mechanisms underlying drug efficacy in vivo. Concomitant studies using human cancer cell lines should be useful for studying mechanisms of drug resistance on a molecular level, and for investigating how that resistance may be overcome. Together these approaches may lead to more effective modes of treatment in the clinic.
